➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Mallinckrodt
Colorcon
Express Scripts
AstraZeneca

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,241,948


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,241,948 protect, and when does it expire?

Patent 9,241,948 protects INFUGEM and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 9,241,948
Title:Ready to be infused gemcetabine solution
Abstract: A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.
Inventor(s): Kumar; Samarth (Vadodara, IN), Kane; Prashant (Vadodara, IN), Namdeo; Alok B. (Vadodara, IN), Bhowmick; Subhas B (Vadodara, IN), Ganorkar; Kirti (Mumbai, IN)
Assignee: Sun Pharmaceutical Industries Ltd. (Mumbai, IN)
Application Number:13/871,438
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,241,948

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-001 Jul 16, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Sun Pharm INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-002 Jul 16, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Sun Pharm INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-003 Jul 16, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Sun Pharm INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-004 Jul 16, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,241,948

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India1334/MUM/2012Apr 27, 2012

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
Mallinckrodt
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.